Minerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017
November 08 2017 - 9:00AM
YASTEST
WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) --
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will present at the Jefferies 2017 London Healthcare
Conference on November 15, 2017 at 2:00 p.m. GMT (9:00 a.m.
EST).
The presentation will be web cast and accessible
through the investor relations section of the Company's web
site, http://ir.minervaneurosciences.com.
About Minerva
Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of products to treat CNS
diseases. Minerva's proprietary compounds include: MIN-101,
in clinical development for schizophrenia; seltorexant (MIN-202 or
JNJ-42847922), in clinical development for insomnia and major
depressive disorder (MDD); MIN-117, in clinical development for
MDD; and MIN-301, in pre-clinical development for Parkinson's
disease. Minerva's common stock is listed on the NASDAQ
Global Market under the symbol "NERV." For more information,
please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Sep 2023 to Sep 2024